5 men and 5 women, with a mean age of 59 years (range 35-68) . The duration of rheumatoid disease ranged from 2 to 35 years, and at least 6 of the patients were seropositive for rheumatoid factor. All the patients had been treated with D-penicillamine, 9 for rheumatoid arthritis and 1 for scleroderma, for a mean period of 16 months (range 3-60). The mean dose of D-penicillamine at the time of marrow depression was 615 mg per day (range 250-1000). Reports on 3 of the patients have already been published (Richards et al., 1976; McAllister and Vale, 1976; Bourke et al., 1976) , and 3 of the cases had been reported to the CSM.
Results
Six of the 10 patients died. Those who survived were given supportive treatment, and the marrow gradually recovered over a period of up to 1 year. In most of these cases the interval between blood counts before the recognition of marrow depression was a month or less over the years preceding treatment with D-penicillamine. Four patients had received chrysotherapy, and in 3 of them the drug had been withdrawn because of an adverse effect; 2 had developed a rash and 1 thrombocytopenia. Another of the patients had phenylbutazone added to her treatment 2 months before developing marrow hypoplasia. Concurrent therapy with other antirheumatic/anti-inflammatory drugs was a feature in the majority of the patients, but full drug histories were not always available.
Discussion
The mechanism of marrow hypoplasia developing in patients on D-penicillamine is not fully understood, but interference by the drug with the synthesis of DNA has been suggested (Chandra and Koch, 1975) . The findings in 7 of the patients in this series suggest that the onset of marrow depression associated with the administration of D-penicillamine is usually gradual, which is consistent with a direct toxic effect on the marrow. A fall in the platelet count within the normal range has been observed in patients treated with D-penicillamine (Weiss et al., 1978) . Leucocytosis and thrombocytosis (Selroos, 1972; Hutchinson et al., 1976) , often observed in active rheumatoid disease, usually settles with the onset of spontaneous or induced remission. In D-penicillamine treated patients this may therefore be due to either a direct or an indirect effect on haemopoiesis. The exact level at which a blood count becomes abnormally low cannot be stated. the persistence, rate, and degree of fall must all be taken into consideration. Plotting the results of blood counts on a semi-logarithmic scale helps to reveal a downward trend (Golton, 1960) and is a routine procedure in oncological practice. Sudden onset of marrow aplasia associated with D-penicillamine therapy has also been reported (Barnett and Whiteside, 1976; Jaffe, 1977-8; Weiss et al., 1978 overwhelming streptococcal infection. It is possible that haemopoiesis may have already been impaired but that the onset of marrow failure became apparent only with increased consumption of leucocytes and platelets associated with the acute infection. It has been suggested that marrow depression may be more common in patients who have previously been treated with gold (Webley and Coomes, 1978) , as had at least 4 of the patients in our series, 1 of the patients had developed thrombocytopenia and 2 of them rashes during chrysotherapy. There is of course a high probability that any patient with long standing rheumatoid disease will have at sometime been exposed to gold treatment. 
)d
The practice of giving lower doses of D-penicillamine and allowing longer intervals between dose increases is now recommended. Jaffe (1977-8) observes that the rate of dose increment appears to be more important than the absolute dose in determining the development of certain side effects. Hill (1977) 
